Table 3 Effect of the combination of biomarkers on the proportion of cases that were biomarker positive and the odds of biomarker positivity in cases compared with controls.
| Combination of biomarkers | No (%) biomarker positive | OR (95% CI) | |
|---|---|---|---|
| Cases* | Controls | ||
| TP53+ve | 11 (32.4%) | 19 (11.7%) | 6.34 (2.11, 19.1) |
| TP53+ve or cyclin D1+ve | 17 (50%) | 68 (41.7%) | 1.68 (0.71, 3.98) |
| TP53+ve or COX‐2+ve | 15 (44.1%) | 44 (27.2%) | 2.67 (1.10, 6.51) |
| TP53+ve or β‐catenin+ve | 11 (33.3%) | 18 (11.2%) | 6.23 (2.06. 18.8) |
| TP53+ve and cyclin D1+ve | 4 (11.8%) | 15 (9.2%) | 1.51 (0.41, 5.61) |
| TP53+ve and COX‐2+ve | 5 (14.7%) | 3 (1.8%) | 27.3 (2.89, 257.0) |
| TP53+ve and β‐catenin+ve | 1 (2.9%) | 2 (1.2%) | 2.48 (0.20, 30.3) |
*Figures relate to oesophageal adenocarcinoma, undifferentiated/unspecified oesophageal carcinomas, and high grade dysplasia
Biomarker positivity = diffuse/intense (grade 2/3) staining.
COX‐2, cyclooxygenase 2; OR (95% CI), odds ratio (95% confidence interval).